International expert consensus on primary systemic therapy in the management of early breast cancer: Highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010)

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 147-151

  Berruti, Alfredo ^a   Generali, Daniele ^b,c   Kaufmann, Manfred ^d   Puztai, Lajos ^e   Curigliano, Giuseppe ^f   Aglietta, Massimo ^g   Gianni, Luca ^h   Miller, William R ⁱ   Untch, Michael ^j   Sotiriou, Christos ^k   Daidone, Mariagrazia ^h   Conte, PierFranco ^l   Kennedy, Derek ^m   Damia, Giovanna ⁿ   Petronini, Piergiorgio ^o   Di Cosimo, Serena ^p   Bruzzi, Paolo ^q   Dowsett, Mitch ^r   Desmedt, Christine ^s   Mansel, Robert E ^t   Olivetti, Lucio ^c   Tondini, Carlo ^u   Sapino, Anna ^a   Fenaroli, Privato ^v   Tortora, Gianpaolo ^w   Thorne, Hather ^x   Bertolini, Francesco ^f   Ferrozzi, Francesco ^o   Danova, Marco ^y   Tagliabue, Elda ^h   de Azambuja, Evandro ^k   Makris, Andreas ^z   Tampellini, Marco ^a   Dontu, Gabriela ^aa   Veer, Laura Van't ^ab   Harris, Adrian L ^ac   Fox, Stephen B ^x   Dogliotti, Luigi ^a   Bottini, Alberto ^a,b,c   more..

^a UNIVERSITY OF TURIN   (Italy)

^b Breast Cancer Unit   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d GOETHE UNIVERSITY   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j HELIOS KLINIKUM BERLIN BUCH   (Germany)

^k UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^l UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^m GRIFFITH UNIVERSITY   (Australia)

ⁿ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^o UNIVERSITY OF PARMA   (Italy)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^q UNIVERSITY OF GENOA   (Italy)

^r ROYAL MARSDEN HOSPITAL   (United Kingdom)

^s JULES BORDET INSTITUTE   (Belgium)

^t CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^u OSPEDALI RIUNITI   (Italy)

^v Bergamo General Hospital   (Italy)

^w UNIVERSITY OF VERONA   (Italy)

^x PETER MACCALLUM CANCER CENTRE   (Australia)

^y FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^z MOUNT VERNON CANCER CENTRE   (United Kingdom)

^aa KING'S COLLEGE LONDON   (United Kingdom)

^ab NETHERLANDS CANCER INSTITUTE   (Netherlands)

^ac UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY SYSTEMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TREATMENT DURATION; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOPSY; BREAST TUMOR; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; ECHOMAMMOGRAPHY; FEMALE; META ANALYSIS (TOPIC); METABOLISM; METHODOLOGY; PALPATION; PATHOLOGY; REMISSION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KI-67 ANTIGEN; META-ANALYSIS AS TOPIC; NEOADJUVANT THERAPY; PALPATION; RECEPTOR, ERBB-2; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, MAMMARY;

EID: 84855180116     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr037     Document Type: Article

References (23)

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005, 97(3): 188-194.
2. Kaufmann M, Morrow M, von Minckwitz G, Harris JR, Biedenkopf Expert Panel Members. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer. 2010, 116(5): 1184-1191.
3. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006, 24(12): 1940-1949.
4. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008, 26(5): 778-785.
5. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006, 93(5): 539-546.
6. Dixon JM, Cody HS III. Role of sentinel node biopsy in patients having neoadjuvant chemotherapy. Eur J Surg Oncol. 2010, 36(6): 511-513.
7. Kühn T, Bauerfeind I, Fehm TN, et al. Sentinel-node biopsy before or after neoadjuvant systemic treatment: the German SENTINA trial. J Clin Oncol. 2010, 28(suppl): 15s. Abstract TPS114.
8. Taran FA, Eggemann H. Breast units in Europe-Certification in 9 European Countries 9 years after the European Society of Mastology Position Paper. Breast Care (Basel). 2009, 4(4): 219-222.
9. Wang L, Jiang Z, Sui M, et al. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer. 2009, 9: 226.
10. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007, 18(12): 1927-1934.
11. Semiglazov VF, Semiglazov VV, Garik AD, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007, 110(2): 244-254.
12. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001, 12(11): 1527-1532.
13. Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007, 25(15): 2012-2018.
14. von Minckwitz G, Kümmel S, Vogel P, et al. German Breast Group. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008, 100(8): 552-562.
15. von Minckwitz G, Untch M, Nüesch E, et al. for the GBG and AGO study groups. Impact of treatment characteristics on response of different breast cancer subtypes: pooled multi-layer analysis of the German neo-adjuvant chemotherapy trials. J Clin Oncol. 2010, 28(suppl): 68s. Abstract 501. ASCO 2010.
16. Jones RL, Lakhani SR, Ring AE, Ashley S, Walsh G, Smith IE. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer. 2006, 94(3): 358-362.
17. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.J Clin Oncol. 2007, 25(19): 2650-2655.
18. Symmans WF, Peintinger F, Hatzis C. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007, 25(28): 4414-4422.
19. Chavez-MacGregor M, Gonzalez-Angulo AM. Breast cancer, neoadjuvant chemotherapy and residual disease. Clin Transl Oncol. 2010, 12(7): 461-467.
20. Pinder SE, Provenzano E, Earl H, et al. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007, 50(4): 409-417.
21. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009, 133(4): 633-642.
22. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005, 11(2, pt 2): 951s-958s.
23. Guix M, Granja Nde M, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008, 26(6): 897-906.